纳武利尤单抗致中毒性表皮坏死松解症1例

doi:10.3969/j.issn.2095-1264.2024.06.18

首页 > 过刊浏览>2024年第6期 >769-773. DOI:10.3969/j.issn.2095-1264.2024.06.18

纳武利尤单抗致中毒性表皮坏死松解症1例
DOI:
                        10.3969/j.issn.2095-1264.2024.06.18
                    
作者:
                        顾融融顾融融
南通大学附属医院 药学部，江苏 南通，226001
在知网中查找
在百度中查找
在本站中查找
陈玲陈玲
南通大学附属医院 药学部，江苏 南通，226001
在知网中查找
在百度中查找
在本站中查找
朱秋燕朱秋燕
南通大学附属医院 药学部，江苏 南通，226001
在知网中查找
在百度中查找
在本站中查找
范小飞范小飞
南通大学附属医院 药学部，江苏 南通，226001
在知网中查找
在百度中查找
在本站中查找
殷晓芹殷晓芹
南通大学附属医院 药学部，江苏 南通，226001
在知网中查找
在百度中查找
在本站中查找

                    
作者单位:南通大学附属医院 药学部，江苏 南通，226001
作者简介:顾融融，女，硕士，主管药师，研究方向为临床药学。
通讯作者:殷晓芹，女，硕士，主任药师，研究方向为临床药学。
中图分类号:R734.2;R979.5
基金项目:

A case report of nivolumab-associated toxic epidermal necrolysis

Author:

GU Rongrong
GU Rongrong
Department of Pharmacy, the Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
在知网中查找
在百度中查找
在本站中查找
CHEN Ling
CHEN Ling
Department of Pharmacy, the Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
在知网中查找
在百度中查找
在本站中查找
ZHU Qiuyan
ZHU Qiuyan
Department of Pharmacy, the Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
在知网中查找
在百度中查找
在本站中查找
FAN Xiaofei
FAN Xiaofei
Department of Pharmacy, the Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
在知网中查找
在百度中查找
在本站中查找
YIN Xiaoqin
YIN Xiaoqin
Department of Pharmacy, the Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
在知网中查找
在百度中查找
在本站中查找

Affiliation:

Department of Pharmacy, the Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

本文报道了１例肺鳞癌患者在使用纳武利尤单抗联合含铂化疗方案后出现中毒性表皮坏死松解症的病例。文章详细描述了该患者的症状，疾病的发生发展、治疗及转归过程，分析其病例特征，并对国内外关于纳武利尤单抗致中毒性表皮坏死松解症的相关报道进行讨论。

关键词:纳武利尤单抗;肺鳞癌;含铂双药化疗;中毒性表皮坏死松解症

Abstract:

Here reported was a case of toxic epidermal necrolysis in a patient with lung squamous cell carcinoma after treatment with nivolumab combined with platinum-based chemotherapy. In this article, we discribed in detail the symptoms, disease development, treatment and outcome of the patient, analyzed the characteristics of the case, and discussed as well the relevant reports on toxic epidermal necrolysis caused by nivolumab at home and abroad.

Key words:Nivolumab;Lung squamous cancer;Platinum-containing double drug chemotherapy;Toxic epidermal necrolysis

参考文献

[1] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. Management of immunotherapy-related toxicities, version 1. 2022, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2022, 20(4): 387-405. DOI: 10.6004/jnccn. 2022.0020.

[2] 王思渊, 鲁辉, 杨纯. PD-1/PD-L1类单抗药物在肿瘤治疗中的应用进展[J]. 中国生物制品学杂志, 2023, 36(1): 105-111. DOI: 10.13200/j.cnki.cjb.003803.

[3] PIRKER R. Immunotherapy combinations in advanced nonsmall cell lung cancer [J]. Curr Opin Oncol, 2021, 33(1): 73-79. DOI: 10.1097/CCO.0000000000000700.

[4] FORDE P M, SPICER J, LU S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer [J]. N Engl J Med, 2022, 386(21): 1973-1985. DOI: 10.1056/NEJMoa2202170.

[5] 佘秋云, 董盈盈, 邓云华. 《2016英国成人Stevens-Johnson综合征/中毒性表皮坏死松解症管理指南》解读[J]. 中国医学文摘-皮肤科学, 2017, 34(3): 273-278.

[6] 刘敏, 李忠东. 实例探讨药物引起SJS或TEN的评分方法——Naranjo评分与ALDEN评分比较[J]. 中国药物应用与监测, 2014, 11(4): 247-249.

[7] BASU P, TONG Y, HINDS B R, et al. Nivolumab-induced toxic epidermal necrolysis with retiform purpura [J]. Br J Dermatol, 2020, 183(2): e32. DOI: 10.1111/bjd.19031.

[8] KEERTY D, KOVERZHENKO V, BELINC D, et al. Immune-mediated toxic epidermal necrolysis [J]. Cureus, 2020, 12(8): e9587. DOI: 10.7759/cureus.9587.

[9] LOGAN I T, ZAMAN S, HUSSEIN L, et al. Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: a case report and literature review [J]. J Immunother, 2020, 43(3): 89-92. DOI: 10.1097/CJI.0000000000000302.

[10] DASANU C A. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma [J]. J Oncol Pharm Pract, 2019, 25(8): 2052-2055. DOI: 10.1177/1078155219830166.

[11] GRIFFIN L L, COVE-SMITH L, ALACHKAR H, et al. Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma [J]. JAAD Case Rep, 2018, 4(3): 229-231. DOI: 10.1016/j.jdcr.2017.09.028.

[12] KOSHIZUKA K, SAKURAI D, SUNAGANE M, et al. Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer [J]. Clin Case Rep, 2020, 9(2): 848-852. DOI: 10.1002/ccr3.3695.

[13] NAYAR N, BRISCOE K, PENAS P F. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma [J]. J Immunother, 2016, 39(3): 149-152. DOI: 10.1097/CJI.0000000000000112.

[14] KIM M C, KHAN H N. Nivolumab-induced toxic epidermal necrolysis: rare but fatal complication of immune checkpoint inhibitor therapy [J]. Cureus, 2021, 13(5): e15017. DOI: 10.7759/cureus.15017.

[15] 谢一航, 沈云, 施辛, 等. 纳武利尤单抗诱导的中毒性表皮坏死松解症1例[J]. 中华皮肤科杂志,2022,55(12):1103-1105. DOI:10.35541/cjd.20200728.

[16] 沈珠, 汪硕闻, 高君伟, 等. 纳武利尤单抗致严重免疫相关皮肤不良反应的病例分析[J]. 中国医院药学杂志, 2021, 41(20): 2150-2153. DOI: 10.13286/j.1001-5213.2021.20.20.

[17] GOLDINGER S M, STIEGER P, MEIER B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy [J]. Clin Cancer Res, 2016, 22(16): 4023-4029. DOI: 10.1158/1078-0432.CCR-15-2872.

[18] 张雪花, 曹雪, 龚操,等. 喹诺酮类药物致Stevens-Johnson综合征和中毒性表皮坏死松解症文献分析[J]. 中国医院药学杂志, 2022, 42(2): 165-171. DOI: 10.13286/j.1001-5213. 2022.02.11.

[19] 刘亚美, 曹育春. 大剂量静脉用丙种球蛋白对重症药疹病情及糖皮质激素使用的影响[J]. 医药导报, 2021, 40(2): 215-219. DOI: 10.3870/j.issn.1004-0781.2021.02.012.